A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

NCT03652610 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

996

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
BIOLOGICAL: Licensed GSK MenACWY vaccine (Menveo)

Sponsor

GlaxoSmithKline